Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Revenue of Madrigal Pharmaceuticals, Inc. (MDGL)
Revenue in 2023 (TTM): $
According to Madrigal Pharmaceuticals, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Madrigal Pharmaceuticals, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-527,000 | $-379,969,000 | $-373,630,000 | $-373,630,000 |
| 2022 | $ | $-467,000 | $-293,104,000 | $-295,350,000 | $-299,314,000 |
| 2021 | $ | $-405,000 | $-242,077,000 | $-241,846,000 | $-241,078,000 |
| 2020 | $ | $-471,000 | $-206,202,000 | $-202,244,000 | $-197,444,000 |
| 2019 | $ | $-112,000 | $-94,860,000 | $-83,948,000 | $-72,812,000 |
| 2018 | $ | $-96,000 | $-40,586,000 | $-32,811,000 | $-32,811,000 |
| 2017 | $ | $-77,000 | $-31,985,000 | $-31,154,000 | $-31,154,000 |
| 2016 | $ | $-156 | $-22,522,844 | $-26,388,000 | $-26,388,000 |
| 2015 | $ | $ | $-3,232,932 | $-68,671,000 | $-68,671,000 |
| 2014 | $ | $ | $-83,278,000 | $-86,161,000 | $-86,161,000 |
| 2013 | $ | $ | $-87,043,000 | $-90,192,000 | $-90,192,000 |
| 2012 | $147 K | $147 K | $-60,203,000 | $-62,790,000 | $-62,790,000 |
| 2011 | $7.58 M | $7.58 M | $-43,968,000 | $-47,380,000 | $-47,380,000 |
| 2010 | $14.8 M | $14.8 M | $-34,965,000 | $-37,467,000 | $-37,467,000 |
| 2009 | $144.25 M | $144.25 M | $81.86 M | $79.09 M | $79.09 M |
| 2008 | $2.62 M | $2.62 M | $-90,991,000 | $-92,618,000 | $-92,618,000 |
| 2007 | $743 K | $743 K | $-62,865,000 | $-122,080,000 | $-63,495,000 |
| 2006 | $ | $ | $-53,615,000 | $-59,129,000 | $-57,270,000 |
| 2005 | $ | $ | $-71,042,000 | $-68,863,000 | $-68,863,000 |
| 2004 | $173 K | $173 K | $-43,799,000 | $-47,517,000 | $-45,934,000 |
| 2003 | $1.3 M | $1.3 M | $-27,288,000 | $-27,878,000 | $-27,878,000 |
| 2002 | $ | $ | $10.8 M | $-54,352,000 | $-36,154,000 |
| 2001 | $ | $ | $-401,000 | $ | $-381,000 |